Assessment of Right Ventricular Function by Cardiac MRI in Patients With Pulmonary Arterial Hypertension (IRMA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulmonary hypertension (PH) is a pathophysiological condition defined by an increase in pulmonary arterial pressure above 20mmHg, which encompasses many very dissimilar conditions. Right ventricular function is the major determinant of survival in these patients. Currently, right ventricular function is estimated by trans-thoracic echocardiography via the measurement of standardised parameters. However, cardiac magnetic resonance imaging is now the reference technique for non-invasive quantification of volumes, mass, function of the right ventricle but can also be useful for the consideration of the pulmonary circulation. Thus, indices of function can be extracted and it plays an increasing role in the prognostic evaluation of the right heart function at diagnosis and at re-evaluation under treatment of pulmonary arterial hypertension. This work will initially focus on the assessment of right ventricular myocardial work by echocardiography and cardiac magnetic resonance imaging in comparison with invasive haemodynamic data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension

NCT01725763

Pulmonary Hypertension Elevated Mean Pulmonary Arterial Pressure Normal Mean Pulmonary Arterial Pressure

ENROLLING_BY_INVITATION NA

Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion

NCT01100008

Pulmonary Hypertension

COMPLETED NA

Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA)

NCT02845518

Pulmonary Arterial Hypertension

RECRUITING NA

Magnetic Resonance Imaging in the Diagnosis of Pulmonary Hypertension

NCT00575692

Pulmonary Hypertension Ventricular Function MR Phase Contrast Velocity Imaging +1 more

COMPLETED

Right Ventricular and Pulmonary Artery Evaluation by CMR

NCT03377673

Pulmonary Hypertension

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cardiac magnetic resonance imaging

all patients had magnetic resonance imaging at baseline and during follow-up.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with pulmonary arterial hypertension (group 1)
* Patient with cardiac MRI, echocardiography and right heart catheterisation within 1 month of each other

Exclusion Criteria

* Patient with features of venous/capillary involvement
* Pulmonary arterial hypertension associated with with congenital heart disease
* Patient's decline to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No